Our data provide strong evidence that combining ATR and TOP1 inhibitors in cancer cells triggers robust immune response signaling and secretion of pro‐inflammatory factors, and thus might transform “cold” tumors into “hot” tumors, which are more likely to respond to systemic immunotherapy. The gene discussed is ATR; the disease is cancer.